Jun 22,2023

Swiss hospital adopts Bayer’s AI platform for radiology

Inselspital at Bern University Hospital is one of the first to take out a subscription to Bayer’s cloud-hosted Calantic Digital Solutions platform in its radiology department and will also work with the German group on real-world evidence (RWE) studies to show the benefits of using AI at scale in clinical settings. Calantic has tools to help radiologists detect and quantify disease lesions in medical images and select patients for treatment in order of priority, improving their productivity. It also includes a curated, vendor-neutral marketplace, allowing radiologists to select from apps with other functions, such as automating routine tasks and measurements, improving radiology suites’ workflow and freeing up time for other tasks. It is expected to be up and running at the hospital’s Institute for Diagnostic and Interventional Neuroradiology within a few months. Calantic launched last year with apps used in thoracic and neurological diseases, such as pulmonary nodule detection and the detection of potential intracerebral haemorrhages (ICH) and large vessel occlusions (LVO), which can be associated with stroke. Since then, it has added apps for breast and prostate diseases.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023

Oncology Care Partners selected the VieCure™ Halo Intelligence platform to provide the best patient experience in cancer care

VieCure today announced the go-live of OCP Miami as a part of VieCure’s strategic partnership with value-based care organization, Oncology Care Partners (“OCP”). The extension of this collaboration will assist OCP in its provision of world-class care to patients across its growing U.S. network, by supporting OCP’s providers in creating personalized treatment plans using VieCure’s Halo Intelligence Platform and helping OCP advance its commitment to overall health equity for its patients.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 20,2023

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Veracyte, Inc. announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology. In addition, findings from an analytical validity study presented at the meeting show that the Afirma TERT promoter mutation test performs with high analytical sensitivity and specificity. During the conference there were 3 different study results from the Afirma molecular testing that were presented. “These data demonstrate that our Afirma molecular testing capabilities and genomic-profile database are valuable tools that can help researchers better understand the genomic underpinnings of thyroid nodules and cancer,” said Joshua Klopper, M.D., Veracyte’s medical director of Endocrinology. “Additionally, our findings reinforce the performance of our TERT promoter mutation test, which we recently began offering with our Afirma Genomic Sequencing Classifier to help advance patient care.” Veracyte’s flagship Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 05,2023

Flatiron welds deal with Lifebit to leverage AI in tracking cancer data

Flatiron Health has inked a multiyear deal with Lifebit, which uses AI to collect biomedical data to advance research and development of treatments targeting cancer. The collaboration will use Lifebit’s technology platform to collect data from hospitals, healthcare providers, research organizations and clinical trials that can then be used in drug development and improved patient care, the companies said in a May 31 press release. Lifebit’s platform is currently being used to support research initiatives by Genomics England, the Danish National Genome Center and NIHR Cambridge Biomedical Research Center. It allows researchers and clinicians to securely analyze data at its point of origin while connecting other data sets without the data being moved or copied.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023 TOP STORY

Flatiron expands oncology work to UK with collaboration deal

Health technology company Flatiron has expanded its global footprint as part of a collaboration deal with Leeds Teaching Hospitals NHS Trust, one of the largest acute hospital trusts in Europe. The goal of the partnership is to produce high-quality oncology data sets that can be used in research collaborations and under license with biopharma companies in order to speed cancer research. Flatiron currently has operations in Japan, Germany and the U.K. that partner with hospitals and health networks in RWD collaborations. In May, Flatiron signed a deal with Sanofi to redesign oncology trials, and in early June the company partnered with AI-focused Lifebit to advance research and development of treatments targeting cancer.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023

Tempus Launches Standalone RNA Sequencing Test, xR

Tempus today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. xR is an option for physicians that are specifically interested in RNA fusions or altered splicing, as well as providers, researchers, and biopharma companies seeking RNA sequencing analysis of existing samples. With the launch of xR, Tempus’ signature xT assay will now perform DNA sequencing, while xR will perform RNA sequencing for clinical and research use.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

Perci Health raises £3.4 million to expand its digital cancer support platform

UK-based digital cancer support clinic, Perci Health has raised £3.4 million seed funding to expand cancer support services. The Seed round was led by Octopus Ventures. Chantel Cox, an investor with the Health team of Octopus ventures will join the Perci Health board. The Perci Health platform offers support to those living with and beyond cancer through personalised programmes. The programmes include support across the whole cancer continuum, from preparing for treatment to support during treatment, recovery and rehabilitation and return to work.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 15,2023 TOP STORY

Digital therapeutic to improve cancer-related well-being: a pilot randomized controlled trial

This randomized waitlist controlled pilot study aimed to evaluate the feasibility and preliminary efficacy of Mika, an app-based digital therapeutic intervention hypothesized to improve management and the support of cancer patients. Patients with gynecological malignancies undergoing post-operative or routine outpatient chemotherapy were randomized (5:2) into intervention (Mika plus treatment-as-usual) and control (treatment-as-usual alone). Feasibility outcomes including dropout rate, reasons for dropout, and intervention adherence, as well as efficacy outcomes including depression, fatigue, and health literacy were assessed at baseline, 4, 8, and 12 weeks. Seventy participants (intervention group, n=50; control group, n=20) with gynecological cancer (ovarian, cervical, and endometrial) were randomized. The dropout rate increased from 15.7% (11/70) between baseline and week 4 to 37.1% (26/70) between weeks 8 and 12. Primary reasons for dropout were death (n=10) and health status deterioration (n=11). Participants in the intervention group showed significant intra-individual reductions in depressive symptoms by 42% (d=0.85) and fatigue symptoms by 23.1% (d=0.5) from baseline to 12 weeks

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023 TOP STORY

Digital therapeutic to improve cancer-related well-being: a pilot randomized controlled trial

This randomized waitlist controlled pilot study aimed to evaluate the feasibility and preliminary efficacy of Mika, an app-based digital therapeutic intervention hypothesized to improve management and the support of cancer patients. Patients with gynecological malignancies undergoing post-operative or routine outpatient chemotherapy were randomized (5:2) into intervention (Mika plus treatment-as-usual) and control (treatment-as-usual alone). Feasibility outcomes including dropout rate, reasons for dropout, and intervention adherence, as well as efficacy outcomes including depression, fatigue, and health literacy were assessed at baseline, 4, 8, and 12 weeks. Seventy participants (intervention group, n=50; control group, n=20) with gynecological cancer (ovarian, cervical, and endometrial) were randomized. The dropout rate increased from 15.7% (11/70) between baseline and week 4 to 37.1% (26/70) between weeks 8 and 12. Primary reasons for dropout were death (n=10) and health status deterioration (n=11). Participants in the intervention group showed significant intra-individual reductions in depressive symptoms by 42% (d=0.85) and fatigue symptoms by 23.1% (d=0.5) from baseline to 12 weeks

CLINICAL STUDY

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

Royal Philips today announced that the Philips-coordinated IMAGIO consortium of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners, to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud and Utrecht University Medical Centers in the Netherlands and University Hospital of Cologne in Germany.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY